ArticleCureus2025
Vitamin C in Sepsis: Exploring Its Role in Modulating Inflammation and Oxidative Stress.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin C for sepsis: from mechanisms to individualized therapy.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Despite improvements in medical treatment, sepsis remains a deadly illness with high fatality rates that is characterized by excessive inflammation and oxidative stress. Objective This study aimed to evaluate the impact of vitamin C supplementation on inflammatory response, oxidative stress, and clinical outcomes in sepsis patients. Methodology A prospective observational study was conducted over one year at Lady Reading Hospital, Peshawar, including 326 adult sepsis cases meeting the Sepsis-3 criteria. To maximize early therapeutic benefits, intravenous vitamin C supplementation (1,500 mg/day) was administered for 14 days, followed by a maintenance regimen of 1,500 mg/day for 14 days every 3-6 months to sustain therapeutic effects. The efficacy of vitamin C was assessed through serial measurements of oxidative stress markers (malondialdehyde) and inflammatory markers (CRP, IL-6, and TNF-α) at baseline and at 3, 6, 9, and 12 months. Clinical outcomes, including ICU stay, organ dysfunction, and mortality, were prospectively recorded. Statistical analysis was performed using SPSS version 25 (IBM Corp., Armonk, NY, USA). Results Vitamin C supplementation in sepsis patients led to significant improvements over 12 months, with reductions in IL-6 (345.16 ± 128.52 to 245.12 ± 83.78 pg/mL), C-reactive protein (CRP) (175.31 ± 62.43 to 114.57 ± 38.67 mg/L), and malondialdehyde (MDA) levels (8.94 ± 3.21 to 5.79 ± 2.18 nmol/mL). Clinical outcomes also improved, including a decrease in the 30-day mortality rate from 14.11% (n=46) to 6.90% (n=22), organ dysfunction score from 9.82 ± 4.03 to 4.83 ± 2.54, and ICU stay from 11.57 ± 3.85 to 7.24 ± 3.01 days. Regression analysis indicated that vitamin C supplementation was significantly associated with better outcomes (β = -2.34, p = 0.012), while chronic kidney disease was associated with worse outcomes (β = 1.75, p < 0.001). Conclusion Supplementing with vitamin C has been shown to significantly improve clinical outcomes in sepsis by lowering oxidative stress and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.